Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Jennifer Oliver
+44 (0)1173310127
jennifer.oliver@bristol.ac.uk


Mrs Madeleine Clout
-
madeleine.clout@bristol.ac.uk


Prof Adam Finn
+44 (0)1173420172
adam.finn@bristol.ac.uk


Dr Catherine Hyams
+44 (0)1174148072
catherine.hyams@bristol.ac.uk


More information about this study, what is involved and how to take part can be found on the study website.

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A pan-pandemic respiratory infection surveillance study
Back

A pan-pandemic respiratory infection surveillance study

Not Recruiting

Open to: All Genders

Age: Adult

Bristol Bristol

Medical Conditions

Acute lower respiratory tract disease (LRTD) - which encompasses pneumonia, lower respiratory tract infection (LRTI), acute bronchitis, exacerbation of underlying respiratory disease including asthma and chronic obstructive pulmonary disease (COPD), as well as COVID-19 (SARS-CoV-2 infection)

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Acute lower respiratory tract disease affects large numbers of people worldwide. Older people are more likely to have disease, suffering both reduced quality of life and increased mortality (death) from respiratory infection. Previous studies have tried to define the burden of respiratory infection in adults, but these studies have been limited as they required patients to have either an identified cause of disease (microbiological diagnosis) or change on a chest X-ray (radiological diagnosis). This has led to an underestimate in disease in adults, because other cases have not been counted.
In 2019, a new virus called SARS-CoV-2 (also referred to as coronavirus) that causes an illness known as COVID-19 emerged and is causing a worldwide pandemic. As the virus is new to humans, people do not have any immunity to it and large numbers of patients are expected to become infected. Researchers do not understand fully how this virus causes disease, nor the risk factors for a poor outcome (including death). They also do not understand how this virus interacts with other bacteria and viruses that cause disease in humans. This is important because if they can determine how these infections interact with each other and the consequences for the patients affected, they may be able to offer better vaccination strategies to prevent disease and treatments to help patients affected. Other diseases important in adult respiratory infection are pneumococcus and RSV (a cold virus). There are potential new vaccines available for use in adults, but as the true amount of disease caused by these infections is not known, researchers cannot determine if using these vaccines in adults would be worthwhile.
The Avon CAP study aims to record all patients admitted with respiratory illness at two hospitals in the Bristol area. The researchers will gather data that has already been recorded by the clinical teams treating these patients, including demographics, comorbidities (other illnesses), outcomes and the results of the investigations undertaken by the medical team. Persons with acute respiratory illness will also be offered participation in the consented portion of this study involving additional testing for pneumococcal and RSV infection, which will identify more cases of such infections than routine testing. The researchers will then use these data to accurately define the true amount of disease caused by respiratory illness and be able to determine the subgroups of disease (for example by patient comorbidity, microbiological and radiological diagnosis) and determine the impact of COVID-19 on respiratory disease.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

01 Aug 2020 30 Jul 2024

Publications

2021 Interim results article in http://dx.doi.org/10.2139/ssrn.3796835 non-peer-reviewed interim results on effectiveness of first dose of COVID-19 vaccines in preprint (added 19/03/2021)2021 Interim results article in https://pubmed.ncbi.nlm.nih.gov/34174190/ Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years (added 07/12/2021)2022 Interim results article in https://doi.org/10.1016/j.lanepe.2022.100473 Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic (added 17/10/2022)2022 Interim results article in https://doi.org/10.1016/j.lanepe.2022.100552 Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022 (added 13/12/2022)2022 Interim results article in https://doi.org/10.1016/j.lanepe.2022.100556 Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults (added 13/12/2022)

The study will collect data already used and gathered in the clinical care of patients. This will include demographic data (e.g. age, gender, smoking status); participant’s comorbidities (e.g. asthma, heart disease, diabetes); vaccination status (e.g. COVID-19 vaccine); clinical presentation (signs/symptoms on admission to hospital, clinical observations such as heart rate); the results of investigations undertaken by the clinical care team (e.g. chest X-ray, blood tests, microbiological tests including COVID-19 results); clinical outcomes (e.g. length of hospital stay, mortality at 30 days, need for organ support or intensive care). The researchers will ask participants to allow them to take either primary research samples (blood, urine and respiratory) or use leftover samples taken from routine clinical care to try to identify respiratory infections.


Any adult aged 18 and over who is admitted to hospital at one of the participating hospitals in the Bristol area, UK.

You can take part if:



You may not be able to take part if:


Patients meeting any of the following criteria will not be included in the study:1. Any patient who develops signs and symptoms of LRTD after being hospitalized for ≥48 hours (either at current hospital, another transferring hospital, or a combination of these), unless admitted with current, previous proven, or suspected COVID-19 infection.2. Previously enrolled participants readmitted ≤7 days after discharge for their study qualifying admission, unless admitted with current, previous proven, or suspected COVID-19 infection3. At the time of enrolment, an LRTD-related diagnosis has been excluded or another diagnosis confirmed (for example, patient was found to have fever and tachypnoea due to an intraabdominal process such as cholecystitis)


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Southmead Hospital
    North Bristol NHS Trust Learning and Research Building
    Bristol
    BS10 5NB
  • Bristol Royal Infirmary
    University Hospitals Bristol and Weston NHS Trust CRIC, St Michael's Hill
    Bristol
    BS2 8DX

There are no direct benefits to taking part in this study, however, participants may feel that they are contributing to the scientific knowledge about COVID-19 and vaccine-preventable infections during the pandemic which may help diagnostics, vaccine development, and future patient care.
The collection of nasal/throat swabs, saliva, blood and urine samples are not thought to pose a significant risk to study participants.
As with all research data of this kind, there are risks to study participants concerning the collection and use of data (e.g. potential identification of study participants, inappropriate access to data). In order to ensure that data protection requirements concerning identifiable data collected through this study, and the right to privacy and confidentiality are maintained, the study will have approval under Section 251 of the NHS Act, undertaken appropriate Data Security Toolkit Assessments, and ensured that all protocols and organisations adhere to GDPR compliance.

Dr Catherine Hyams
+44 (0)1174148072
catherine.hyams@bristol.ac.uk


Dr Jennifer Oliver
+44 (0)1173310127
jennifer.oliver@bristol.ac.uk


Mrs Madeleine Clout
-
madeleine.clout@bristol.ac.uk


Prof Adam Finn
+44 (0)1173420172
adam.finn@bristol.ac.uk



More information about this study, what is involved and how to take part can be found on the study website.


The study is sponsored by University of Bristol and funded by Pfizer.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN17354061
Last updated 08 October 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top